| Rated↑ Article |
|---|
Upload Add-on :: Convus :: Add-ons for FirefoxRated 2023-03-10T15:55:34-0800 - seth
|
The effect of short-term high-caloric feeding and fasting on bone microarchitecture - ScienceDirectRated 2023-03-18T20:43:34-0700 - sethherr
Rated 2023-03-19T10:11:07-0700
-
Jaog
|
https://www.texasattorneygeneral.gov/sites/default/files/images/admin/2021/Press/DC%20Statehood%20letter%20as%20sent%20(02539672xD2C78)%20(002).pdfRated 2023-03-21T18:17:49-0700 - cindy
|
Faster sorting algorithms discovered using deep reinforcement learningFundamental algorithms such as sorting or hashing are used trillions of times on any given day1. As demand for computation grows, it has become critical for these algorithms to be as performant as possible. Whereas remarkable progress has been achieved in the past2, making further improvements on the efficiency of these routines has proved challenging for both human scientists and computational approaches. Here we show how artificial intelligence can go beyond the current state of the art by... 2023-06-07T00:00:00-0700 Nature Mankowitz, Daniel J., Michi, Andrea, Zhernov, Anton, Gelmi, Marco, ... 10,000 words Rated 2023-06-07T23:48:39-0700 - sethherr
|
NP-hard does not mean hardWhen NP-hardness pops up on the internet, say because some silly blogger wants to write about video games, it's often tempting to conclude that the problem being proved NP-hard is actually very hard! "Scientists proved Super Mario is NP-hard? I always knew there was a reason I wasn't very good at it!" Sorry, these two… 2017-12-29T13:30:23-0800 Math ∩ Programming 2,000 words Rated 2023-08-17T01:02:50-0700 - sethherr
|
I wired up my bike's GPS to order me pizza during a gravel race 🍕As harvest season begins here in the Midwest, I once again celebrate by grinding Nebraska gravel at the Gravel Worlds Long Voyage bike race. As in previous… steele.blue 1,000 words Rated 2023-09-10T06:38:08-0700 - Jaog
|
Gilead’s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung CancerGilead’s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer gilead.com 3,000 words Rated 2023-09-17T21:23:25-0700 - sethherr
|